FRAGMENT AND FRAME SIZES Clause Samples

FRAGMENT AND FRAME SIZES. This IA does not recommend any specific fragment size. The fragment size is configured in the transmitter, and two peer transmitters need not use the same fragment size. For End-to-End fragmentation, the maximum fragment size used on a particular PVC depends on both the access line speeds at the two ends of the connection, the speeds of any NNI interfaces on the path, and the delay and delay variation requirements of the particular applications in use on the PVC. The maximum fragment size to send should be configured on a per-PVC basis. If one or more of the Frame Relay network(s) interconnecting the DTEs are implemented using FRF.5 [4] FR/ATM Network Interworking, then it may be advantageous to make the End-to-End fragment size (not including the FCS) an even multiple of the underlying ATM cell payload size in order to optimize the performance at the ATM layer. See FRF.5 [4] for additional details on how the end-to-end fragments are carried in ATM cells. Also see Appendix A for an additional discussion of End-to-End fragment size considerations in this case. For UNI and NNI fragmentation, the maximum fragment size should be configured on a per-interface basis. The optimal fragment size for these interfaces is the result of a tradeoff between the efficiencies of large frames, the MTU size of the constituent networks, and the required delay and delay variation characteristics of the applications. Receivers must be able to reassemble complete frames up to at least 1600 octets in length.
View Source

Related to FRAGMENT AND FRAME SIZES

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Security of All Software Components Supplier will inventory all software components (including open source software) used in Deliverables, and provide such inventory to Accenture upon request. Supplier will assess whether any such components have any security defects or vulnerabilities that could lead to a Security Incident. Supplier will perform such assessment prior to providing Accenture with access to such software components and on an on-going basis thereafter during the term of the Agreement. Supplier will promptly notify Accenture of any identified security defect or vulnerability and remediate same in a timely manner. Supplier will promptly notify Accenture of its remediation plan. If remediation is not feasible in a timely manner, Supplier will replace the subject software component with a component that is not affected by a security defect or vulnerability and that does not reduce the overall functionality of the Deliverable(s).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).